The functional impact of migraine during and between attacks can be measured using the Migraine-Specific Quality-of-Life Questionnaire (MSQ)1-3
The MSQ RF-R is a valid measure of the functional impact of migraine1,2
This tool consists of 7 questions that assess how migraine limits the social and work-related activities of patients. Patient responses are rated on a 100-point scale, with 0 points being most impacted and 100 points being least impacted.1,2
The questions of the RF-R domain of the MSQ v2.1 include1:
- Have migraines interfered with how well you dealt with family, friends, and others who are close to you?
- Have migraines interfered with your leisure time activities, such as reading or exercising?
- Have you had difficulty in performing work or daily activities because of migraine symptoms?
- Did migraines keep you from getting as much done at work or at home?
- Did migraines limit your ability to concentrate on work or daily activities?
- Have migraines left you too tired to do work or daily activities?
- Have migraines limited the number of days you felt energetic?
For patients with 4-14 MHDs per month,
Emgality significantly improved patients' migraine-specific quality of life during and in between attacks2,3

Patients on Emgality experienced a statistically significant improvement in the functional impact of migraine over Months 4 to 6.1
EVOLVE-1 mean improvement in MSQ v2.1 RF-R scores: Emgality 120 mg demonstrated a mean improvement of 32.4 points from baseline (N=189), demonstrating less impact of migraine, vs 24.7 points with placebo (N=377) over Months 4 to 6.1a Baseline: 51.4 vs 52.9 points.

EVOLVE-2 mean improvement in MSQ v2.1 RF-R scores: Emgality 120-mg demonstrated a mean improvement of 28.5 points from baseline (N=213), demonstrating less impact of migraine, vs 19.7 points with placebo (N=396) over Months 4 to 6.1a Baseline: 52.5 vs 51.4 points.
- In REGAIN, statistical significance vs placebo was not observed after controlling for multiple comparisons for mean change in MSQ v2.1 RF-R3
ap<0.001 vs placebo.
See study designs for EVOLVE-1 and EVOLVE-2 and REGAIN.
References:
- Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52:409-421.
- Speck RM, Shalhoub H, Wyrwich KW, et al. Psychometric validation of the Role Function Restrictive domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache. 2019;59:756-774.
- Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.